EVERSANA’s Post

Read the blog: https://ow.ly/YCiM50S31if EVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies. #BreastCancer #Oncology Sarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz Samjoo

📊HR+, HER2-, high-risk early breast cancer #monarchE clinical trial update: >96% completion rate in baseline PRO, the data reveals that QoL scales exhibit consistent trends within and between arms, highlighting minimal differences in diarrhea at 3 and 6 months. During treatment, 69-78% of patients reported experiencing minimal side effects, indicating the favorable profile of adjuvant #abemaciclib. Post-treatment PROs align with baseline, reinforcing the therapy's tolerable and reversible toxicity profile. Read the full article here: https://ow.ly/5fyU50Qt2Gk #MedEd #bcsm

The journey of a breast cancer patient is challenging enough without the added burden of CIPN, chemotherapy-induced peripheral neuropathy, a devastating side effect of taxane-based chemotherapies. Listen in as our CEO, Bob Linke, explains how Osmol's OSM-0205 aims to prevent nerve damage, allowing patients to continue their life-saving treatments without compromising their quality of life. Learn more at our lead candidate as we prepare to initiate clinical development later this year for OSM-0205: https://bit.ly/4c4jFHj #biopharma #oncology #clinicaltrials

Selective omission of RT in rectal cancer - Jun Gong Neeraj Agarwal, MD, FASCO American Society of Clinical Oncology (ASCO) Katelyn Atkins Cedars-Sinai https://lnkd.in/eehvduSY #OncoDaily #Oncology #Cancer #Health #Medicine #RectalCance

Unlock precision in cancer care with the Oncolife Head & Neck Panel. It helps in curating tailored treatments, anticipates resistance, and reduces unnecessary side effects. Ideal for early detection and ongoing monitoring. For more information,call 8046985101, 8061970525 #headandneck #HeadandNeckCancer #awareness #headandneckcancerawareness #oncology #cancerdetection #cancercare #cancerdetection #lifecellin #lifecelldiagnostics

Highlighting the challenges myeloma patients face around clinical trials Myeloma Patients Europe (MPE) https://lnkd.in/dA3dg4EQ #BloodCancerAwarenessMonth #Cancer #ClinicalTrials #EuropeanMyelomaDay #Myeloma #ClinicalTrials #MyelomaPatients #OncoDaily #Oncology

Understand how the Breast Cancer Index® test identifies patients with a low risk of late distant recurrence, helping to personalize extended endocrine therapy treatment decisions. Learn from our recent webinar to help avoid over- and under-treatment. Watch here: https://bit.ly/3zv9aPx

The new treatment concepts in pancreatic cancer in the CECOG masterclass - Eric Van Cutsem Christoph Zielinski https://lnkd.in/eZkMt-dy #OncoDaily #Oncology #Cancer #Health #Medicine #PancreaticCancer #CancerTreatment

Practical guidance for sotorasib-related adverse events prevention and hepatotoxicity management - Michael Duruisseaux https://lnkd.in/ghW8fydZ #oncodaily #oncology #cancer #LungCancerJournal #Sotorasib #AdverseEvents #Hepatotoxicity #MedicalGuidance #FrenchExpertise #MedicalResearch

Dr. Sarika Gupta, an esteemed Consultant in Gynae-Surgical Oncology at RGCIRC, recently provided valuable insights in her interview with Door Darshan (DD). She focused on the vital topics of Cervical and Prostate Cancer, discussing their symptoms, detection methods, and the newest advancements in treatment. #ProstateCancerAwareness #OncologyUpdates #HealthcareInnovation #DrSarikaGupta #RGCIRC #CancerResearch #MedicalExpertise #DoorDarshanInterview